Alpha 2.0
Login Register
» Authors » H van der Wijngaart

H van der Wijngaart

Explore the profile of H van der Wijngaart including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 124
Followers 0
Related Specialties
Oncology
General Medicine
Science
Top 10 Co-Authors
H M W Verheul
J M van Berge Henegouwen
E E Voest
L R Hoes
H Gelderblom
E van Werkhoven
A D R Huitema
P Roepman
D L van der Velden
L J Zeverijn
Published In
Neth J Med
Cancer Chemother Pharmacol
Ann Oncol
Eur J Cancer
Nature
Affiliations
Soon will be listed here.
Recent Articles
1.
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)
Verkerk K, Zeverijn L, van de Haar J, Roepman P, Geurts B, Spiekman A, et al.
ESMO Open . 2025 Jan; 10(1):104112. PMID: 39778224
Background: Many patients with cancer exhibit primary or rapid secondary resistance to targeted therapy (TT). We hypothesized that a higher number of altered oncogenic signaling pathways [pathway alteration load (PAL)]...
2.
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
van Berge Henegouwen J, Jebbink M, Hoes L, van der Wijngaart H, Zeverijn L, van der Velden D, et al.
Eur J Cancer . 2022 Jun; 171:114-123. PMID: 35716537
Introduction: In 1-3% of non-small cell lung cancer (NSCLC) human epidermal growth factor 2 (HER2) mutations are identified as a genomic driver. Nevertheless, no HER2-targeted treatment is approved for NSCLC....
3.
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature
van Berge Henegouwen J, van der Wijngaart H, Zeverijn L, Hoes L, Meertens M, Huitema A, et al.
Cancer Chemother Pharmacol . 2022 May; 90(1):97-104. PMID: 35598186
Introduction: The combination of vemurafenib, a proto-oncogene B-Raf inhibitor (BRAFi) and cobimetinib, an inhibitor of mitogen-activated protein kinase kinase (MEKi) has shown to improve survival in patients with BRAF V600-mutated...
4.
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
van der Velden D, Hoes L, van der Wijngaart H, van Berge Henegouwen J, van Werkhoven E, Roepman P, et al.
Nature . 2019 Oct; 574(7776):127-131. PMID: 31570881
The large-scale genetic profiling of tumours can identify potentially actionable molecular variants for which approved anticancer drugs are available. However, when patients with such variants are treated with drugs outside...
5.
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
van Waalwijk van Doorn-Khosrovani S, Pisters-van Roy A, van Saase L, van der Graaff M, Gijzen J, Sleijfer S, et al.
Ann Oncol . 2019 May; 30(5):663-665. PMID: 31038154
No abstract available.
6.
A 73-year-old male with jaundice and acute kidney injury. Bile cast nephropathy
van der Wijngaart H, van Dam B, van den Berg J, Krul-Poel Y, Klemt-Kropp M, Bax W
Neth J Med . 2014 Mar; 72(2):95, 99. PMID: 24659594
No abstract available.